Janux Therapeutics, Inc. Common Stock (JANX)

Price$13.36

Value ScoreC

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-68.73%

Price vs S&P 500 (4W)-5.74%

VGM Score53.35

Market Capitalization$814.75M

All Metrics

Book Value / Share (Quarterly)$15.47

P/TBV (Annual)1.33x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.12%

Cash Flow / Share (Quarterly)$-1.29

Price vs S&P 500 (YTD)-11.35%

Net Profit Margin (TTM)-354.43%

EPS (TTM)$-1.84

10-Day Avg Trading Volume0.78M

EPS Excl Extra (TTM)$-1.84

EPS (Annual)$-1.83

ROI (Annual)-6.74%

Net Profit Margin (5Y Avg)-827.80%

Cash / Share (Quarterly)$15.71

Revenue Growth QoQ (YoY)2177.90%

ROA (Last FY)-6.50%

Revenue Growth TTM (YoY)47.10%

EBITD / Share (TTM)$-2.49

ROE (5Y Avg)-29.83%

Operating Margin (TTM)-505.82%

Cash Flow / Share (Annual)$-0.75

P/B Ratio0.87x

P/B Ratio (Quarterly)0.90x

Net Income / Employee (Annual)$-1,042,400

EV / Revenue (TTM)55.55x

Net Interest Coverage (TTM)-2.49x

ROA (TTM)-11.20%

EPS Incl Extra (Annual)$-1.83

Current Ratio (Annual)60.82x

Quick Ratio (Quarterly)16.95x

3-Month Avg Trading Volume1.05M

52-Week Price Return-46.04%

Revenue / Employee (TTM)$126,000

Tangible BV / Share (Quarterly)$7.56

P/S Ratio (Annual)81.48x

Asset Turnover (Annual)0.01x

52-Week High$35.34

Operating Margin (5Y Avg)-1019.40%

EPS Excl Extra (Annual)$-1.83

26-Week Price Return-60.81%

Quick Ratio (Annual)60.32x

13-Week Price Return-4.37%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)17.01x

Enterprise Value$762.92M

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$91,700

Pretax Margin (Annual)-1136.25%

Cash / Share (Annual)$17.37

3-Month Return Std Dev34.36%

Net Income / Employee (TTM)$-1,050,300

ROE (Last FY)-6.74%

EPS Basic Excl Extra (Annual)$-1.83

Receivables Turnover (TTM)11.06x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.84

ROI (TTM)-11.85%

P/S Ratio (TTM)59.33x

Pretax Margin (5Y Avg)-827.80%

Revenue / Share (Annual)$0.16

Tangible BV / Share (Annual)$7.71

Price vs S&P 500 (52W)-70.41%

Year-to-Date Return-3.19%

5-Day Price Return-7.29%

EPS Normalized (Annual)$-1.83

ROA (5Y Avg)-17.92%

Net Profit Margin (Annual)-1136.25%

Month-to-Date Return-8.43%

Cash Flow / Share (TTM)$-1.42

EBITD / Share (Annual)$-2.51

Operating Margin (Annual)-1576.67%

ROI (5Y Avg)-29.83%

EPS Basic Excl Extra (TTM)$-1.84

P/TBV (Quarterly)1.22x

P/B Ratio (Annual)3.02x

Pretax Margin (TTM)-354.43%

Book Value / Share (Annual)$17.34

Price vs S&P 500 (13W)-12.62%

Beta2.55x

Revenue / Share (TTM)$0.22

ROE (TTM)-11.85%

52-Week Low$12.12

vGradeC

gGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.39est. -0.54

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.23

4.12

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
JANXJanux Therapeutics, Inc. Common Stock	C	A	D	$13.36
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Janux Therapeutics is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies designed to treat cancer by engaging the patient's immune system. The company has developed proprietary platforms, including TRACTr (tumor-activated T cell engagers) and TRACIr (tumor-activated immunomodulators), that combine tumor-targeting with immune activation mechanisms. These approaches aim to activate anti-cancer immune responses specifically at tumor sites, potentially improving efficacy and safety compared to conventional cancer treatments.